Cargando…

Targeted Molecular Therapy in Glioblastoma

Detalles Bibliográficos
Autores principales:	Festuccia, Claudio, Biordi, Assunta Leda, Tombolini, Vincenzo, Hara, Akira, Bailey, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201507/ https://www.ncbi.nlm.nih.gov/pubmed/32411237 http://dx.doi.org/10.1155/2020/5104876

Ejemplares similares

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma
por: Gravina, Giovanni Luca, et al.
Publicado: (2022)

Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma
por: Colapietro, Alessandro, et al.
Publicado: (2021)

The Botanical Drug PBI-05204, a Supercritical CO(2) Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties
por: Colapietro, Alessandro, et al.
Publicado: (2020)

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)

Immunometabolism: Molecular Mechanisms, Diseases, and Therapies
por: Rosa Neto, José Cesar, et al.
Publicado: (2014)

The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)

Immunometabolism: Molecular Mechanisms, Diseases, and Therapies 2016
por: Rosa Neto, Jose C., et al.
Publicado: (2017)

The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy
por: Mattei, Vincenzo, et al.
Publicado: (2021)

Immunometabolism: Molecular Mechanisms, Diseases, and Therapies 2018
por: Rosa, José C., et al.
Publicado: (2019)

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2018)

Identification of Molecular Targets and Anti-Cancer Agents in GBM: New Perspectives for Cancer Therapy
por: D’Amico, Agata Grazia, et al.
Publicado: (2023)

Targeting anticancer drug-induced senescence in glioblastoma therapy
por: Tomicic, Maja T., et al.
Publicado: (2018)

Molecular and Cellular Mechanisms of Glioblastoma
por: Castresana, Javier S., et al.
Publicado: (2021)

Hypoxia and glioblastoma therapy
por: Yang, Chunzhang, et al.
Publicado: (2015)

Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
por: Gravina, Giovanni L, et al.
Publicado: (2010)

Molecular Biology in Glioblastoma Multiforme Treatment
por: Abbruzzese, Claudia, et al.
Publicado: (2022)

ET-04 MOLECULAR TARGETED THERAPY AGAINST (PRO)RENIN RECEPTOR FOR GLIOBLASTOMA
por: Fujimori, Takeshi, et al.
Publicado: (2019)

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
por: Festuccia, C., et al.
Publicado: (2018)

Glioblastoma Biology, Genetics and Possible Therapies
por: Castresana, Javier S., et al.
Publicado: (2023)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
por: González-Mora, Andrea Magali, et al.
Publicado: (2021)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Cancer Prevention with Molecular Targeted Therapies
por: Paleari, Laura
Publicado: (2022)

Dopamine signaling: target in glioblastoma
por: Bartek, Jiri, et al.
Publicado: (2014)

Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma
por: Colapietro, Alessandro, et al.
Publicado: (2020)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Radiation therapy and serum salivary amylase in head and neck cancer
por: De Felice, Francesca, et al.
Publicado: (2017)

Glioblastomas
por: Finocchiaro, Gaetano, et al.
Publicado: (2021)

Prostate Cancer: From Molecular Imaging to Immunological and Target Therapies
por: Filippi, Luca, et al.
Publicado: (2023)

Discernable differences in the genetic and molecular profile of cerebellar glioblastoma
por: Tora, Muhibullah S., et al.
Publicado: (2019)

UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice
por: Festuccia, Claudio, et al.
Publicado: (2018)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

UDP-α-D-glucose 6-dehydrogenase: a promising target for glioblastoma
por: Goodwin, C. Rory, et al.
Publicado: (2019)

Targeted alpha therapy for glioblastoma
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

New section in journal of translational medicine: patient-targeted molecular therapies
por: Bot, Adrian, et al.
Publicado: (2012)

Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?
por: Barra, Fabio, et al.
Publicado: (2019)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ouc5j7m1uocdt7r6i2moph4hgl